Harsh Vardhan
@harsh.vardhan.9098
Jodhpur
5+ Years of experience
SEBI Registration INH000011006
Trade Ideas
118
Opinions
190
Followers
342
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 6th Sep
Wockhardt: Biotech Growth & Pharma Recovery Ahead
WOCKPHARMA
Wockhardt is showing a meaningful earnings recovery, with Q1 FY27 consolidated revenue rising 26% YoY to ₹929 crore and PAT turning positive at ₹107 crore versus a ₹108 crore loss in Q1 FY26. EBITDA increased 86% YoY, while biotech revenue surged 112% to ₹236 crore, highlighting strong momentum in the higher-value business.
Latest News: India branded business grew 21% to ₹156 crore, supported by diabetes therapy, Emrok and regenerative dermatology. Wockhardt also secured multiple international approvals and launched new products, strengthening its global pipeline.
Corporate Action/Catalysts: FY26 EBITDA increased 51% to ₹630 crore, while the company raised ₹1,000 crore through a QIP, providing capital for growth investments. Upcoming insulin-analogue launches could become a major catalyst. Key risks remain regulatory compliance, execution, R&D spending and the sustainability of the recent earnings turnaround. shared an insight ⚡️ 6th Sep
Alkem Laboratories: Strong Domestic Pharma Momentum
ALKEM
Alkem Laboratories delivered Q1 FY27 revenue growth of 10.9% YoY to ₹3,740 crore, while EBITDA rose 3.7% to ₹766 crore. PAT declined 21.7% to ₹520 crore, largely reflecting the high base and tax impact. Domestic sales grew 10.3% to ₹2,498 crore, outperforming the Indian pharma market, while US sales increased 6.5% to ₹744 crore.
Latest News: Alkem launched semaglutide in India in March 2026 and became the first Indian company to launch it in single-shot pre-filled syringes in June, with pricing starting at ₹350. The company also received 5 ANDA approvals in Q1.
Corporate Action/Catalysts: Alkem had ₹5,764 crore net cash at June 2026 and continues investing in R&D, with Q1 R&D spend at ₹150 crore. Strong domestic brands, semaglutide potential and US launches provide growth catalysts. Key risks include US pricing pressure, regulatory issues and margin moderation. shared an insight ⚡️ 6th Sep
Aurobindo Pharma: Strong Growth & Global Scale
AUROPHARMA
Aurobindo Pharma delivered a strong Q1 FY27, with revenue rising 16.3% YoY to ₹9,150 crore and PAT increasing 25.2% to ₹1,033 crore. PBT rose 25.6% to ₹1,515 crore, while operating profit reached ₹1,354 crore. Growth was broad-based across key markets, supported by new US launches and improved operating performance.
Latest News: The company continues expanding its US and European formulations portfolio, while its injectable and specialty businesses provide additional growth avenues. Management is also consolidating its Eugia business structure through the proposed merger of Eugia Steriles & SEZ with Eugia Pharma.
Corporate Action/Catalysts: New product launches, strong US growth, injectable capacity and specialty pharma expansion could support earnings. The balance between growth and margin improvement remains attractive. Key risks include US pricing pressure, regulatory observations, currency movements and execution risks on complex products.FAQ's
What are the top stock recommendations by Harsh Vardhan?
Harsh Vardhan regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include WOCKPHARMA, ALKEM and AUROPHARMA. Explore Harsh Vardhan's complete list of posts and trade views on their StockGro profile.
How can I follow Harsh Vardhan's latest investment insights?
You can follow Harsh Vardhan's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Harsh Vardhan's investment strategy?
Harsh Vardhan follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Harsh Vardhan been a SEBI-registered Research Analyst (RA)?
Harsh Vardhan has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Harsh Vardhan's past performance and stock picks?
You can check Harsh Vardhan's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Harsh Vardhan for stock market advice?
For stock market guidance from Harsh Vardhan, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Harsh Vardhan's track record in predicting market movements?
Harsh Vardhan has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Harsh Vardhan?
Harsh Vardhan is a SEBI-registered Research Analyst with the SEBI Registration INH000011006. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro